vs
克瑞（CR）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
克瑞的季度营收约是Royalty Pharma plc的1.1倍（$696.4M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 9.6%，领先24.8%），克瑞同比增速更快（24.9% vs 4.8%），过去两年克瑞的营收复合增速更高（14.8% vs 4.6%）
克瑞是总部位于美国康涅狄格州斯坦福德的工业产品企业，1855年由理查德·泰勒·克兰创立。公司曾是美国领先卫浴配件制造商，1990年出售该业务板块，1960年起逐步转型为多元化控股集团，当前核心业务涵盖航空航天与电子、工程材料、流体处理、控制系统四大板块，服务化工等多个行业领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CR vs RPRX — 直观对比
营收规模更大
CR
是对方的1.1倍
$622.0M
营收增速更快
CR
高出20.1%
4.8%
净利率更高
RPRX
高出24.8%
9.6%
两年增速更快
CR
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $696.4M | $622.0M |
| 净利润 | $67.1M | $214.2M |
| 毛利率 | 40.4% | — |
| 营业利润率 | 14.4% | 62.4% |
| 净利率 | 9.6% | 34.4% |
| 营收同比 | 24.9% | 4.8% |
| 净利润同比 | -37.3% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRRPRX
| Q1 26 | $696.4M | — | ||
| Q4 25 | $581.0M | $622.0M | ||
| Q3 25 | $589.2M | $609.3M | ||
| Q2 25 | $577.2M | $578.7M | ||
| Q1 25 | $557.6M | $568.2M | ||
| Q4 24 | $544.1M | $593.6M | ||
| Q3 24 | $548.3M | $564.7M | ||
| Q2 24 | $528.6M | $537.3M |
净利润CRRPRX
| Q1 26 | $67.1M | — | ||
| Q4 25 | $81.7M | $214.2M | ||
| Q3 25 | $91.4M | $288.2M | ||
| Q2 25 | $86.4M | $30.2M | ||
| Q1 25 | $107.1M | $238.3M | ||
| Q4 24 | $81.0M | $208.2M | ||
| Q3 24 | $77.3M | $544.0M | ||
| Q2 24 | $71.6M | $102.0M |
毛利率CRRPRX
| Q1 26 | 40.4% | — | ||
| Q4 25 | 41.6% | — | ||
| Q3 25 | 42.7% | — | ||
| Q2 25 | 42.0% | — | ||
| Q1 25 | 42.6% | — | ||
| Q4 24 | 40.9% | — | ||
| Q3 24 | 41.4% | — | ||
| Q2 24 | 40.0% | — |
营业利润率CRRPRX
| Q1 26 | 14.4% | — | ||
| Q4 25 | 17.5% | 62.4% | ||
| Q3 25 | 20.1% | 70.1% | ||
| Q2 25 | 17.8% | 36.3% | ||
| Q1 25 | 18.1% | 94.0% | ||
| Q4 24 | 15.8% | 60.9% | ||
| Q3 24 | 18.1% | — | ||
| Q2 24 | 16.9% | 50.2% |
净利率CRRPRX
| Q1 26 | 9.6% | — | ||
| Q4 25 | 14.1% | 34.4% | ||
| Q3 25 | 15.5% | 47.3% | ||
| Q2 25 | 15.0% | 5.2% | ||
| Q1 25 | 19.2% | 41.9% | ||
| Q4 24 | 14.9% | 35.1% | ||
| Q3 24 | 14.1% | 96.3% | ||
| Q2 24 | 13.5% | 19.0% |
每股收益（稀释后）CRRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.40 | $0.49 | ||
| Q3 25 | $1.56 | $0.67 | ||
| Q2 25 | $1.47 | $0.07 | ||
| Q1 25 | $1.83 | $0.55 | ||
| Q4 24 | $1.37 | $0.46 | ||
| Q3 24 | $1.33 | $1.21 | ||
| Q2 24 | $1.23 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $355.4M | $618.7M |
| 总债务越低越好 | $1.2B | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $4.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CRRPRX
| Q1 26 | $355.4M | — | ||
| Q4 25 | $506.5M | $618.7M | ||
| Q3 25 | $388.2M | $938.9M | ||
| Q2 25 | $332.2M | $631.9M | ||
| Q1 25 | $435.1M | $1.1B | ||
| Q4 24 | $306.7M | $929.0M | ||
| Q3 24 | $258.2M | $950.1M | ||
| Q2 24 | $229.3M | $1.8B |
总债务CRRPRX
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $247.0M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益CRRPRX
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $2.0B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | $1.8B | $9.8B | ||
| Q4 24 | $1.6B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.5B | $9.8B |
总资产CRRPRX
| Q1 26 | $4.1B | — | ||
| Q4 25 | $3.9B | $19.6B | ||
| Q3 25 | $2.5B | $19.3B | ||
| Q2 25 | $2.5B | $18.3B | ||
| Q1 25 | $2.6B | $17.6B | ||
| Q4 24 | $2.6B | $18.2B | ||
| Q3 24 | $2.7B | $18.0B | ||
| Q2 24 | $2.5B | $17.7B |
负债/权益比CRRPRX
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.56× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.15× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-40.2M | — |
| 自由现金流率自由现金流/营收 | -5.8% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $361.5M | — |
8季度趋势，按日历期对齐
经营现金流CRRPRX
| Q1 26 | — | — | ||
| Q4 25 | $205.8M | $827.1M | ||
| Q3 25 | $130.2M | $702.6M | ||
| Q2 25 | $105.0M | $364.0M | ||
| Q1 25 | $-46.2M | $596.1M | ||
| Q4 24 | $202.0M | $742.5M | ||
| Q3 24 | $75.4M | $703.6M | ||
| Q2 24 | $51.3M | $658.2M |
自由现金流CRRPRX
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $196.0M | — | ||
| Q3 25 | $116.8M | — | ||
| Q2 25 | $88.9M | — | ||
| Q1 25 | $-60.4M | — | ||
| Q4 24 | $188.2M | — | ||
| Q3 24 | $67.3M | — | ||
| Q2 24 | $44.6M | — |
自由现金流率CRRPRX
| Q1 26 | -5.8% | — | ||
| Q4 25 | 33.7% | — | ||
| Q3 25 | 19.8% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | -10.8% | — | ||
| Q4 24 | 34.6% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 8.4% | — |
资本支出强度CRRPRX
| Q1 26 | 1.5% | — | ||
| Q4 25 | 1.7% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.3% | — |
现金转化率CRRPRX
| Q1 26 | — | — | ||
| Q4 25 | 2.52× | 3.86× | ||
| Q3 25 | 1.42× | 2.44× | ||
| Q2 25 | 1.22× | 12.06× | ||
| Q1 25 | -0.43× | 2.50× | ||
| Q4 24 | 2.49× | 3.57× | ||
| Q3 24 | 0.98× | 1.29× | ||
| Q2 24 | 0.72× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CR
| Process Flow Technologies | $378.1M | 54% |
| Aerospace & Advanced Technologies | $318.3M | 46% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
